VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2015

Dec 18, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2015-12-16

Reporting Person: BOGER JOSHUA S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-12-16	Common Stock	M	10400	$35.64	Acquired	275684	Direct
2015-12-16	Common Stock	S	2000	$114.72	Disposed	273684	Direct
2015-12-16	Common Stock	S	2600	$115.72	Disposed	271084	Direct
2015-12-16	Common Stock	S	4400	$116.47	Disposed	266684	Direct
2015-12-16	Common Stock	S	400	$117.73	Disposed	266284	Direct
2015-12-16	Common Stock	S	1000	$118.81	Disposed	265284	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-12-16	Stock Option (right to buy)	$35.64	M	10400	Disposed	2016-02-01	Common Stock (10400)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	13286	Indirect
Common Stock	122700	Indirect

Footnotes

F1: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

F2: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3: Open market sales reported on this line occurred at a weighted average price of $114.72 (range $114.20 to $115.19).

F4: Open market sales reported on this line occurred at a weighted average price of $115.72 (range $115.20 to $116.04).

F5: Open market sales reported on this line occurred at a weighted average price of $116.47 (range $116.21 to $117.15).

F6: Open market sales reported on this line occurred at a weighted average price of $117.73 (range $117.42 to $117.92).

F7: Open market sales reported on this line occurred at a weighted average price of $118.81 (range $118.52 to $119.21).

F8: Fully vested.